Clinical trials: Cancer of Nasopharynx
Head and Neck Cancer
Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00002922
- Testing
- paclitaxel
- Where
- 24 sites in United States, South Africa
- Sponsor
- Eastern Cooperative Oncology Group
Nasopharyngeal Carcinoma, PD-1
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Conditions
- Nasopharyngeal Carcinoma, PD-1, Surgery
- Trial name
- NCT04778956
- Testing
- Toripalimab, salvage surgery
- Where
- 7 sites in China
- Volunteers
- 218 people
- Sponsor
- Sun Yat-sen University
GM-CSF
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
To evaluate the efficacy of GM-CSF to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy.
- Trial name
- NCT06472739
- Testing
- GM-CSF
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
We define refractory nasopharyngeal carcinoma as the following: recurrence with radiation brain injury after radiotherapy, recurrence after the second or more courses of radiotherapy, standard treatment failure after recurrence…
- Trial name
- NCT02590133
- Testing
- Recombinant Human Endostatin Injection (Endostar), Fluorouracil (5-Fu), Nedaplatin
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Yun-fei Xia
Nasopharyngeal Carcinoma
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
- Trial name
- NCT04220528
- Testing
- Capecitabine/Tiggio
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Cancer
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy .
- Trial name
- NIVONASO-21 (NCT04875611)
- Testing
- Opdivo
- Where
- 4 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Head and Neck Cancer, Lymphedema
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
RATIONALE: Developing a symptom checklist for late-effect lymphedema may help doctors learn more about lymphedema in patients with head and neck cancer and plan the best treatment.
- Trial name
- NCT00840814
- Where
- 3 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02434614
- Testing
- Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Recurrent or Metastatic NPC
Nasopharyngeal Carcinoma (NPC) Axitinib
This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of single-agent axitinib in recurrent or metastatic NPC patients who failed at least one line of platinum based chemotherapy.
- Trial name
- NCT01249547
- Testing
- axitinib
- Where
- Hong Kong
- Volunteers
- 37 people
- Sponsor
- Chinese University of Hong Kong
Head and Neck Cancer
Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Using a customized headrest to hold patients in one position may help doctors plan treatment for patients with head and neck cancer.
- Trial name
- NCT00973947
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, radiation therapy treatment planning/simulation
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
High Risk Locally Advanced Nasopharyngeal Carcinoma
TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma
We expect to conduct a clinical trial in high-risk locally advanced nasopharyngeal carcinoma patients to explore the efficacy and safety of sequential radical radiotherapy treatment after induction chemotherapy (TPC vs.
- Trial name
- NCT06561763
- Testing
- Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00978081
- Testing
- aminolevulinic acid hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis, Ultrasonography and Shear Wave Elastography
Evaluation of Swallowing Muscles Using Ultrasonography and Shear Wave Elastography in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis
The aim of this study is to evaluate the mylohyoid, geniohyoid and digastric muscles in patients with radiotherapy-induced dysphagia due to nasopharynx cancer using ultrasonography and shear wave elastography (SWE).
- Conditions
- Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis, Ultrasonography and Shear Wave Elastography, Evaluation of Swallowing Muscles
- Trial name
- NCT06934837
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Konya Beyhekim Training and Research Hospital
Nasopharynx Cancer, Head and Neck Cancer
U87 CAR-T in Patients With Advanced Head and Neck Tumors
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U87 injection solution in patients with advanced malignant head and neck tumors.
- Trial name
- NCT06614686
- Testing
- U87 autologous CAR T-cell
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563927
- Testing
- Conventional RT, Cisplatin, 5-fluorouracil
- Where
- 4 sites in China
- Volunteers
- 340 people
- Sponsor
- Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients.
- Conditions
- Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
- Trial name
- NCT05941741
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Radiotherapy; Complications
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT05780372
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy
- Where
- 7 sites in China
- Volunteers
- 474 people
- Sponsor
- Sun Yat-sen University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial is studying how well giving carboplatin, paclitaxel, cetuximab, and erlotinib hydrochloride together works in treating patients with metastatic or recurrent squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01316757
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.